机构风向标 | 灵康药业(603669)2025年二季度已披露持仓机构仅1家

Core Insights - Lingkang Pharmaceutical (603669.SH) released its semi-annual report for 2025 on August 23, 2025, indicating significant institutional investment [1] Group 1 - As of August 22, 2025, there is one institutional investor that disclosed holding shares in Lingkang Pharmaceutical, totaling 340 million shares, which represents 47.09% of the company's total equity [1] - The institutional investor includes Lingkang Holdings Group Co., Ltd., contributing to the overall institutional holding percentage of 47.09%, which remains unchanged [1]